Zoladex 3-Month Depot Implant Is Approved

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 23 No 5
Volume 23
Issue 5

WILMINGTON, Del--Zeneca Pharmaceuticals has received clearance from the FDA to market a new formulation of Zoladex (goserelin acetate implant) for the palliative treatment of advanced prostate cancer.

WILMINGTON, Del--Zeneca Pharmaceuticals has received clearancefrom the FDA to market a new formulation of Zoladex (goserelinacetate implant) for the palliative treatment of advanced prostatecancer.

The new formulation, a 10.8-mg goserelin acetate implant givenevery 3 months, offers greater convenience to patients choosingtreatment with a luteinizing-hormone-releasing hormone (LHRH)analog, the company said.

The original 1-month 3.6-mg formulation of Zoladex implants hasbeen available in the United States since 1989 for the treatmentof advanced prostate cancer. The drug has been marketed since1993 for the treatment of endometriosis, and it was recently clearedby the FDA for the treatment of advanced breast cancer in premenopausaland perimeno-pausal women.

Articles in this issue
Earlier Unrelated BMT Is Effective in CML Subgroup
Taxol/Cisplatin Extends Survival in Advanced Ovarian Ca
Prostate Cancer Patients Face a Host of Psychosocial Issues
NSABP to Study Docetaxel in Operable Breast Cancer
Panel Recommends Approval of Talc for Malignant Pleural Effusions
ODAC Recommends Approval of Verluma for Staging of SCLC
Minorities Lack Internet Access to Cancer Research Data
Fludarabine Produces CRs as First-Line CLL Therapy
M.D. Anderson's C. Stratton Hill Receives Award From American Cancer Society
Managed Care: The View From Salick Managed Care
Selling 'High Risk' Part of an Oncology Practice Can Increase Financial Stability
Entries Are Sought for Kushner Writing Award
Docetaxel Effective as First-Line Breast Cancer Therapy
Roswell Park Institute Establishes Hepatic Cryosurgery Center
High-Dose RAIT May Improve Prognosis in Relapsed NHL Patients

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
1 expert in this video
1 expert in this video
1 expert in this video
Multidisciplinary collaboration may help in minimizing the treatment burden among patients with prostate cancer, according to Curtiland Deville Jr., MD.
4 experts in this video
Related Content
Landmark Radioligand Therapy Approval Bridges Treatment Gap in mCRPC

Landmark Radioligand Therapy Approval Bridges Treatment Gap in mCRPC

Ariana Pelosci
April 18th 2025
Article

Administering 177Lu for mCRPC is a “team sport”, according to Steven Finkelstein, MD, DABR, FACRO.

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD
March 5th 2025
Podcast

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

Pembrolizumab/Docetaxel Does Not Improve OS/rPFS Outcomes in mCRPC

Pembrolizumab/Docetaxel Does Not Improve OS/rPFS Outcomes in mCRPC

Tim Cortese
April 15th 2025
Article

Results from the KEYNOTE-921 trial demonstrated that pembrolizumab with docetaxel did not elicit efficacy improvements vs placebo with docetaxel in prostate cancer.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
July 1st 2024
Podcast

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.

FDA Approves Radioligand Therapy in PSMA–Positive, Castration-Resistant PC

Tim Cortese
March 28th 2025
Article

Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.

Post-Radical Prostatectomy PSA Levels Reduced Overtreatment Risk After 3 Months

Post-Radical Prostatectomy PSA Levels Reduced Overtreatment Risk After 3 Months

Tim Cortese
March 26th 2025
Article

A cohort study found that pre-radical prostatectomy levels greater than 20 ng/mL were associated with increased all-cause mortality risk and prostate cancer-specific mortality risk.